Chronic urticaria is a condition where itchy, raised welts appear on the skin repeatedly for more than six weeks, often without a clear reason. While these hives can be uncomfortable and frustrating, there are treatment approaches available to help manage symptoms and improve quality of life.

Understanding How Treatment Helps Manage Chronic Urticaria

When someone develops chronic urticaria, the main goals of treatment focus on reducing the frequency and severity of hives, controlling the intense itching that often accompanies them, and helping people return to their normal daily activities without constant discomfort. Unlike acute hives that disappear within days or weeks, chronic urticaria persists for at least six weeks and can last for months or even years in some cases. This makes finding an effective management strategy particularly important for maintaining quality of life.^[1]

Treatment approaches for chronic urticaria depend on several factors, including how severe the symptoms are, how often hives appear, and whether any triggers can be identified. For most people, the cause remains unknown—this is why the condition is sometimes called chronic idiopathic urticaria, where “idiopathic” means the cause is not clear. About 80% to 90% of chronic urticaria cases fall into this category, making treatment focused on symptom control rather than addressing a specific underlying cause.^[4]

Medical organizations and expert panels have established guidelines for treating chronic urticaria based on years of research and clinical experience. These recommendations help doctors choose the most appropriate treatments for their patients. At the same time, researchers continue to study new medications and approaches in clinical trials, offering hope for people whose symptoms don’t respond well to currently available treatments.^[2]

Standard Treatment Approaches

The cornerstone of chronic urticaria treatment involves medications called antihistamines, which work by blocking the effects of histamine—a chemical released by mast cells in the skin that causes the itching, redness, and swelling characteristic of hives. Mast cells are specialized immune cells that play a central role in allergic reactions and inflammatory responses. When they release histamine and other substances, blood vessels in the skin leak fluid, creating the raised, itchy welts people experience.^[1]

Modern treatment guidelines strongly recommend starting with second-generation or non-sedating antihistamines as the first line of therapy. These medications include cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine, and rupatadine. The advantage of these newer antihistamines is that they provide effective symptom relief without causing significant drowsiness or affecting a person’s ability to think clearly and perform daily tasks. This makes them much more suitable for long-term use compared to older antihistamines.^[12]

Healthcare providers typically recommend taking these antihistamines daily rather than only when hives appear. Regular daily use has been shown to improve quality of life more effectively than taking medication on an as-needed basis. The consistent presence of the medication in the body helps prevent hives from forming rather than just treating them after they appear.^[6]

If standard doses of second-generation antihistamines don’t adequately control symptoms, doctors may increase the dose gradually, up to four times the usual recommended amount. This approach is supported by clinical guidelines and has been shown to help many patients who don’t respond to standard doses. For example, someone taking 10 mg of cetirizine daily might have their dose increased to 20 mg, then 30 mg, and potentially up to 40 mg if needed. About 75% of patients referred to specialty centers for difficult-to-treat chronic urticaria require these higher doses to achieve adequate symptom control.^[15]

For severe flare-ups that significantly impact quality of life, doctors may prescribe a short course of oral corticosteroids such as prednisone. A typical regimen might include prednisone at a dose of 0.3 to 0.5 mg per kilogram of body weight for one to two weeks, followed by a gradual taper. However, corticosteroids are not recommended for long-term use due to their potential side effects, which can include weight gain, elevated blood sugar, increased infection risk, and bone thinning with prolonged use.^[23]

Some patients benefit from adding other types of medications to their treatment plan. Leukotriene receptor antagonists such as montelukast may be added to antihistamine therapy. These medications block a different inflammatory pathway and can provide additional symptom relief when combined with antihistamines. H2 antihistamines like ranitidine or famotidine, which are typically used for heartburn, are sometimes prescribed alongside H1 antihistamines by some doctors, though the evidence for their effectiveness in chronic urticaria is less robust.^[10]

Another medication option is doxepin, a tricyclic antidepressant that has strong antihistamine effects. Doxepin can be particularly helpful for nighttime symptoms because it helps with both itching and sleep. However, it must be used with caution, especially in older adults and people with certain heart conditions or glaucoma. Doctors may recommend electrocardiogram monitoring if higher doses are needed.^[15]

Treatment duration varies considerably from person to person. Some people find their hives resolve within months, while others require treatment for years. More than half of patients with chronic urticaria experience improvement or complete resolution within one year, though about 20% may have symptoms that persist for longer periods. The unpredictable nature of the condition means treatment often needs to be adjusted over time based on how symptoms respond.^[6]

Side effects from second-generation antihistamines are generally mild, even at higher doses. Some people may experience headache, dry mouth, or mild drowsiness, though these effects are much less pronounced than with first-generation antihistamines. The safety profile of these medications makes them suitable for long-term use in most patients. However, individuals should discuss any concerns about side effects with their healthcare provider.^[12]

Advanced Treatments in Clinical Trials

For patients whose chronic urticaria doesn’t respond adequately to antihistamines, even at increased doses, several advanced treatment options are being studied in clinical trials or have recently received approval for use. These treatments represent important breakthroughs for people living with difficult-to-control symptoms.

The most significant advance in recent years has been the approval and use of omalizumab (brand name Xolair), a biologic medication that works differently from traditional antihistamines. Biologics are medications made from living cells that target very specific parts of the immune system. Omalizumab is a monoclonal antibody—a laboratory-made protein designed to bind to and block immunoglobulin E (IgE), an antibody that plays a key role in allergic reactions and appears to be involved in chronic urticaria.^[9]

Omalizumab was the first biologic medication approved by the U.S. Food and Drug Administration specifically for treating chronic spontaneous urticaria in people 12 years and older whose symptoms are not adequately controlled by H1 antihistamines. The medication works by binding to IgE molecules in the blood before they can attach to mast cells. This prevents the activation of mast cells and reduces the release of histamine and other inflammatory substances that cause hives.^[14]

The medication is given as a subcutaneous injection—meaning it’s injected under the skin—once a month at a dose of either 150 mg or 300 mg. In clinical trials, omalizumab demonstrated significant effectiveness in reducing both the frequency and severity of hives, as well as the intensity of itching. Many patients experienced substantial improvement in their quality of life. The treatment can be administered in a doctor’s office or, for appropriate patients, may be approved for self-injection at home using a prefilled syringe or autoinjector device.^[14]

Clinical trials for omalizumab have shown that many patients experience meaningful symptom reduction within weeks of starting treatment. The medication has been studied in multiple Phase III trials—the final stage of testing before approval, where the new treatment is compared with standard care in large groups of patients. These studies confirmed both its effectiveness and safety profile for chronic urticaria.^[9]

Another biologic that has recently been approved for chronic spontaneous urticaria is dupilumab. This medication works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13), which are proteins involved in inflammatory processes. By inhibiting these specific inflammatory pathways, dupilumab can help reduce symptoms in some patients with chronic urticaria.^[9]

For cases that remain resistant to these treatments, immunosuppressive medications may be considered. Cyclosporine is one such medication that has been studied for chronic urticaria. It works by suppressing the immune system more broadly, which can help reduce the inflammatory response causing hives. However, because of potential side effects including kidney function changes and increased blood pressure, cyclosporine requires careful monitoring through regular blood tests.^[10]

Other immunosuppressive agents being studied or used in some cases include methotrexate, hydroxychloroquine, mycophenolate, and tacrolimus. These medications affect different aspects of immune function and may benefit patients who haven’t responded to other treatments. Because they can have more significant side effects than antihistamines, their use is typically reserved for severe cases and requires close medical supervision with regular laboratory monitoring.^[10]

Some clinical trials are exploring other novel approaches. Research continues into the underlying mechanisms of chronic urticaria, particularly the autoimmune aspects of the condition. About 30% to 50% of patients with chronic urticaria have circulating autoantibodies—antibodies that mistakenly target the body’s own tissues. In these cases, the autoantibodies attack IgE or the receptors on mast cells that bind IgE, leading to mast cell activation and histamine release. Understanding this autoimmune component has opened new avenues for targeted therapies.^[4]

Researchers are also investigating medications that target different aspects of mast cell activation and the inflammatory cascade. Tyrosine kinase inhibitors, which affect cell signaling pathways, are being studied for their potential role in chronic urticaria treatment. These medications work by blocking specific enzymes involved in cellular communication and activation processes.^[15]

Clinical trials for chronic urticaria are conducted in various locations around the world, including the United States, Europe, and other regions. Patients interested in participating in clinical trials should discuss options with their healthcare provider. Participation requirements typically include having a confirmed diagnosis of chronic urticaria, evidence that standard treatments have been inadequate, and meeting specific health criteria that vary by study.^[2]

The different phases of clinical trials serve distinct purposes. Phase I trials primarily assess safety and determine appropriate dosing in small groups of participants. Phase II trials examine whether the treatment is effective and continue to evaluate safety in larger groups. Phase III trials compare the new treatment with current standard treatments in even larger populations to confirm effectiveness and monitor side effects. Many of the advanced treatments now available for chronic urticaria have successfully completed this rigorous testing process.^[4]

Most common treatment methods

• Second-generation antihistamines
  • Medications include cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine, and rupatadine
  • Work by blocking histamine effects to reduce itching, redness, and swelling
  • Recommended as first-line treatment taken daily
  • Can be increased up to four times standard doses if needed
  • Have minimal sedating effects compared to older antihistamines
• Corticosteroids
  • Short courses of prednisone for severe flare-ups
  • Typical dose is 0.3 to 0.5 mg per kilogram of body weight for one to two weeks
  • Not recommended for long-term use due to side effects
• Leukotriene receptor antagonists
  • Montelukast may be added to antihistamine therapy
  • Block a different inflammatory pathway to provide additional relief
• Biologic therapies
  • Omalizumab (Xolair) is a monoclonal antibody that binds to IgE
  • Given as monthly injections of 150 mg or 300 mg under the skin
  • Approved for chronic urticaria not controlled by antihistamines in people 12 years and older
  • Dupilumab blocks interleukin-4 and interleukin-13 inflammatory pathways
• Immunosuppressive medications
  • Cyclosporine suppresses immune system activity to reduce inflammation
  • Requires regular monitoring through blood tests
  • Other options include methotrexate, hydroxychloroquine, mycophenolate, and tacrolimus
  • Reserved for severe cases not responding to other treatments
• Other medications
  • Doxepin, a tricyclic antidepressant with strong antihistamine effects
  • H2 antihistamines like ranitidine or famotidine may be added by some doctors